Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur CHI DUC NGUYEN

📍 Béthune (62)HospitalierRPPS 10101381050
📚 HAL (3)

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (2)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

  • Le docteur Nguyen, nouveau rhumatologue de l’hôpital d’Helfaut - Delta FM

    📰 Delta FM · 22/07/2019

    <a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOMzIwM0dBLUQ2Q0EtRGtoeGxHdWxFVkFKd1gzUlV4bzhwMFdrVjgwRHRMblgtblBFMzN3QkNRNnFlMjk4R0NsTnVzYXR5Z0V0M3pULVhZS3hmRHRlcnNnbjZLYnVuLU9OMzBPYVFjcW93bUV0cVJ3R0NmY0N4Z042M0JDVm9hSFFLOERWNlItOEZMdw?oc=5" target="_blank">Le docteur Nguyen, nouveau rh

  • Helfaut : un rhumatologue au centre hospitalier - L'Echo de la Lys - Nord Littoral

    📰 Nord Littoral · 28/06/2019

    <a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQUHp3RUhlUTZjWjd0V2hTOWlYNjcwRFhENXFpcFB3MG9NTGM3eUEyMW9LUWZOQlVZVi1LNG1LbmVOZmlsTHJ5WVNIZFVTenNlTWNnSkE3YXg0TUs5MU5EV3hGaXQ5Ti05aXF2MWxYOTdtbkRqLXQ0RVMxNGtvN2hTOXNwOGp5cFFTWVlST0VNY0VPVHBSaW1YNTIxbHVWZjg?oc=5" target="_blank">Helfaut : un

Top publications · les plus citées

  • 1
    Inherited retinal disease-associated uveitis

    Survey of ophthalmology · 2025

    📚 4 citations
  • 2
    Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 study

    Nature communications · 2025

    📚 2 citations🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
  • 3
    Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical Data

    JCO oncology practice · 2025

    📚 2 citations
    Lire l'abstract Crossref ↓

    PURPOSE The treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved in recent years with the use of tyrosine kinase inhibitors (TKIs) and immuno-oncology (IO) therapies. This study examined patient characteristics, treatment patterns, health care resource utilization (HCRU), costs, and survival for individuals with mRCC who received either IO + IO or IO + TKI combinations as first-line (1L) regimens. METHODS This retrospective cohort study used integrated claims and clinical data from a commercial health plan to study adults with mRCC who began 1L treatment between April 1, 2018, and January 31, 2023. Patient characteristics, 1L and second-line (2L) regimens, and HCRU were described. Costs were summarized per patient per month over time. Survival time was analyzed overall and partitioned into time on 1L, treatment-free survival, and survival after 2L. RESULTS Patients receiving 1L IO + IO (n = 471) or IO + TKI (n = 353) regimens generally had similar baseline characteristics although among patients with risk data, 33% of IO-IO patients versus 23% of IO-TKI patients had poor risk scores. Treatment costs were higher for IO + IO in the first 3 months but lower in subsequent time intervals compared with IO + TKI. Total mean costs per patient were $720K in US dollars (USD) for IO + IO and $834K USD for IO + TKI over the course of 3 years. Medication costs represented 80% of total costs. IO + IO patients stayed on 1L therapy for a shorter duration, but cumulative survival time at 24 months was the same (63%) for both groups. CONCLUSION Patients receiving 1L IO + IO and IO + TKI regimens had similar baseline characteristics and comparable survival at 30 months. Although IO + IO was associated with higher treatment costs in the first 3 months, the subsequent monthly costs were lower compared with IO + TKI.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal35

▼

Essai clinique4

▼

Vraie vie / RWE4

▼

Épidémiologie & registres2

▼

Revue / méta-analyse2

▼

Sjögren2

▼

Activité physique / Rééducation1

▼

Économie santé1

▼

Pédiatrie1

▼

Pharmacovigilance1

▼

Qualité de vie / PROMs1

▼

Revue générale1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.